Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that Rellidep will be effective in improving the symptoms of
major depression. The available evidence strongly suggests that Rellidep contains a mood
altering ingredient or ingredients. This open-label, non-randomized study sets out to
validate its potential antidepressant activity.The study will include secondary aims of
evaluating the effect of Rellidep on reducing symptoms of anxiety, a common symptom
associated symptom of depression and improving quality of life.
About twenty-five patients with major depressive disorder will be assigned to open-label
Rellidep (2000 mg/day) for a period of 8 weeks. All patients will be assessed by various
measures of global improvement, depression, quality of life, sexual experience, anxiety and
measures of side effects as well as standard laboratory tests.